Literature DB >> 19190529

Common variable immunodeficiency.

Francisco A Bonilla1, Raif S Geha.   

Abstract

Common variable immunodeficiency is the most prevalent clinically significant antibody deficiency at all ages. The disorder is defined principally by characteristic infection susceptibility with hypogammaglobulinemia and impaired-specific antibody response. Several recent large registry-based studies have defined distinct phenotypic subtypes. Several studies have also correlated specific immunologic markers with these phenotypes. The biochemical or genetic abnormality in the majority of patients remains unknown. Recently, several molecular genetic lesions have been defined. Among these, mutations of inducible costimulator, and CD19, appear to be disease causing by themselves. These account for about 1% of cases. Other mutations or polymorphisms, such as in the human homolog of Escherichia coli MutS 5 (MSH5), and transmembrane activator and calcium mobilizing ligand interactor, seem to be disease associated in 5-10% of patients, but may require additional immunologic abnormalities for full expression of the phenotype, as unaffected heterozygotes have also been described.

Entities:  

Mesh:

Year:  2009        PMID: 19190529     DOI: 10.1203/PDR.0b013e31819dbf88

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  6 in total

1.  Homozygous deficiency of ubiquitin-ligase ring-finger protein RNF168 mimics the radiosensitivity syndrome of ataxia-telangiectasia.

Authors:  S S Devgan; O Sanal; C Doil; K Nakamura; S A Nahas; K Pettijohn; J Bartek; C Lukas; J Lukas; R A Gatti
Journal:  Cell Death Differ       Date:  2011-03-11       Impact factor: 15.828

2.  A Novel de Novo Mutation in the CD40 Ligand Gene in a Patient With a Mild X-Linked Hyper-IgM Phenotype Initially Diagnosed as CVID: New Aspects of Old Diseases.

Authors:  Tábata T França; Luiz F B Leite; Tiago A Maximo; Christiane G Lambert; Nuria B Zurro; Wilma C N Forte; Antonio Condino-Neto
Journal:  Front Pediatr       Date:  2018-05-04       Impact factor: 3.418

3.  TNFRSF13B Diversification Fueled by B Cell Responses to Environmental Challenges-A Hypothesis.

Authors:  Marilia Cascalho; Jeffrey L Platt
Journal:  Front Immunol       Date:  2021-02-17       Impact factor: 7.561

4.  Multi-omics analysis of naïve B cells of patients harboring the C104R mutation in TACI.

Authors:  Neftali Ramirez; Sara Posadas-Cantera; Niko Langer; Andres Caballero Garcia de Oteyza; Michele Proietti; Baerbel Keller; Fangwen Zhao; Victoria Gernedl; Matteo Pecoraro; Hermann Eibel; Klaus Warnatz; Esteban Ballestar; Roger Geiger; Claudia Bossen; Bodo Grimbacher
Journal:  Front Immunol       Date:  2022-08-16       Impact factor: 8.786

5.  PTIP chromatin regulator controls development and activation of B cell subsets to license humoral immunity in mice.

Authors:  Dan Su; Stijn Vanhee; Rebeca Soria; Elin Jaensson Gyllenbäck; Linda M Starnes; Martina Kubec Højfeldt; Gabriel K Pedersen; Joan Yuan; Jeremy A Daniel
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-16       Impact factor: 11.205

6.  Urine stem cells are equipped to provide B cell survival signals.

Authors:  Asmaa A Zidan; Griffith B Perkins; Mohammed Al-Hawwas; Ahmed Elhossiny; Jianyu Yang; Larisa Bobrovskaya; Ghada M Mourad; Xin-Fu Zhou; Plinio R Hurtado
Journal:  Stem Cells       Date:  2021-02-13       Impact factor: 6.277

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.